Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. (Q36642141)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Lajos Pusztai

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

21 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

621-632

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and northern blot: a comparison

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

A paradigm for class prediction using gene expression profiles

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

The molecular portraits of breast tumors are conserved across microarray platforms

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Prediction of docetaxel response in human breast cancer by gene expression profiling.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Gene expression profile associated with response to doxorubicin-based therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0636

7 January 2021

Identifiers

DOI

10.1038/NCPONC0636

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17080180%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference